AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19
March 23, 2021 | 11:10
The AstraZeneca US Phase III trial of AZD1222 demonstrated 79 per cent vaccine efficacy at preventing symptomatic COVID-19 and 100 per cent efficacy at preventing severe disease and hospitalisation.
Mobile Version